LACTERA / PROPRIETARY BIOTECHNOLOGY PLATFORM
DEVELOPMENT FOCUS
Evidence-led innovation for complex healing pathways.
01 / ABOUT US
LACTERA is a Delaware C-Corp advancing a rigorous commercialization pathway across wound care and regenerative medicine. Our founding team joins global strategy, fermentation biotechnology, bioactive materials, reconstructive surgery, and clinical leadership.
Chief Executive Officer
Led by an experienced executive overseeing Global Strategy & Investor Relations. Bringing extensive commercialization expertise to navigate the regulatory landscape and drive institutional financing for advanced wound care and regenerative therapeutics.
Founding Chairman
Guided by a pioneer in Fermentation Biotechnology & Bioactive Materials. Expertly scaling up proprietary bioprocesses and overseeing the synthesis of bioactive materials required for continuous product improvement and commercial readiness.
Chief Medical Officer
Supervised by a leading Reconstructive Surgeon providing elite Clinical Leadership. Ensuring evidence-based development and coordinating clinical trial collaborations with major hospitals for optimal patient outcomes.
Honda Hsu serves as Founding Chair of the Medical & Scientific Advisory Board.
02 / TECHNOLOGY & PRODUCTS
Our platform is designed to advance healing environments through bioactive materials, scalable biotechnology, and a disciplined development strategy for targeted clinical applications.
Diabetic wound care
Post-surgical healing
Acute & chronic wounds
Explore Technology Platform
03 / CLINICAL & RESEARCH
Our clinical-development strategy is anchored in real-world learning, structured evidence generation and the 2026 British Journal of Dermatology randomised controlled trial in diabetic foot ulcers.
FEATURED CLINICAL EVIDENCE / BJD / JUNE 2026
Randomised controlled trial in diabetic foot ulcers — British Journal of Dermatology, 2026.
PUBLISHED STUDY REFERENCES
1. Chao-Chih Yang, Meng-Si Wu, Honda Hsu. Management of diabetic foot ulcers using topical probiotics in a soybean-based concentrate: A multicentre study. J Wound Care. 2023 Dec 1;32:S16-S21.
2. Honda Hsu, Chao-Chih Yang, Shih-Ming Huang, Meng-Si Wu, Hui-e Yao, Yi-Wei Lin. Topical Probiotics in Soybean Concentrate for Diabetic Foot Ulcers: A Randomised Controlled Trial. British Journal of Dermatology, Volume 194, Issue 6, June 2026, Pages 1192–1194.
Review Clinical Evidence
1. Chao-Chih Yang, Meng-Si Wu, Honda Hsu. Management of diabetic foot ulcers using topical probiotics in a soybean-based concentrate: A multicentre study. J Wound Care. 2023 Dec 1;32:S16-S21.
2. Honda Hsu, Chao-Chih Yang, Shih-Ming Huang, Meng-Si Wu, Hui-e Yao, Yi-Wei Lin. Topical Probiotics in Soybean Concentrate for Diabetic Foot Ulcers: A Randomised Controlled Trial. British Journal of Dermatology, Volume 194, Issue 6, June 2026, Pages 1192–1194.
04 / PARTNERSHIPS
LACTERA’s international strategy is designed to align clinical development, licensing, and market access across key innovation ecosystems.
United States
Israel
Ukraine
Taiwan
Asia-Pacific
05 / CONTACT
Forward-Looking Statements Disclaimer: This website may contain forward-looking statements relating to anticipated development activities, product candidates, clinical research, regulatory pathways, partnerships, and business strategy. These statements involve risks and uncertainties, and actual results may differ materially. Nothing on this website constitutes medical advice, an offer to sell, or a solicitation of an offer to buy securities.
Corporate updates